Pharmaceutical industry in the dark over data protection changes

Pharmaceutical professionals across the UK are in danger of underestimating the huge changes that lie ahead in data protection – after a survey revealed almost a third aren’t even aware of the forthcoming European General Data Protection Regulation.

The Regulation, due to be discussed again by the EU Commission, European Parliament and the Council of the EU, is predicted to be ratified in the next twelve months and in place during 2017 – but when information management experts Crown Records Management commissioned a Censuswide Survey of IT decision makers at UK companies with more than 200 employees, to test how well prepared businesses are for the changes, it revealed 28% of IT decision makers in the pharmaceutical sector are totally unware of the changes – only the insurance sector came out worse.

In addition, almost one third say they are waiting for the final details of the Regulation before taking any action, and 33% say their company is looking a staff training to prepare for the new regulation – the lowest across all sectors. 6% are not planning to make any changes at all.

John Culkin, Director of Information Management at Crown Records Management, says, “These results shows UK businesses, and particularly those in the pharmaceutical industry, are worryingly uninformed when it comes to preparing for the EU General Data Protection Regulation.

“It’s a concern that a third of businesses in the pharmaceutical sector are unaware of the big changes ahead, but the important question is not just whether businesses are worried or not, but whether they are being proactive and taking early action to prepare for the Regulation.

“The results did show that more than half in the sector are planning to review information policies, and that’s important. Also 45% have already appointed a Data Protection Officer, which is likely to be compulsory for many companies in future, and that’s the best figure across all sectors.

“Overall, our advice is that companies should begin an information audit as soon as possible and make positive changes as early as possible. With big fines for data breaches in future and strict guidelines on how quickly breaches should be reported there is work to do for many businesses across all sectors.”


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...